Imuger

Azathioprine, the active ingredient in Imuger, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ rejection and to manage autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus.

GNH USA supplies Imuger as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imuger (azathioprine) is used across several immune‑mediated disease pathways, providing long‑term suppression of abnormal immune activity. - Organ transplantation: helps prevent graft rejection by inhibiting lymphocyte proliferation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): controls intestinal inflammation and maintains remission. - Systemic lupus erythematosus: diminishes systemic auto‑immune activity and organ damage.

Azathioprine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring early in therapy. - Loss of appetite: reduced desire to eat, often transient. - Mild leukopenia: slight decrease in white blood cell count, monitored regularly. - Elevated liver enzymes: mild hepatic enzyme rise detectable on routine labs.

Serious or Rare Side Effects: - Severe leukopenia or agranulocytosis: marked drop in white cells increasing infection risk. - Hepatotoxicity: significant liver injury requiring discontinuation. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Increased malignancy risk: rare but possible long‑term risk of lymphomas and skin cancers.

Before initiating Imuger, several safety considerations should be addressed. - Monitor blood counts: perform baseline and periodic CBC to detect leukopenia. - Assess liver function: check hepatic enzymes before and during treatment. - Avoid use in active infection: defer therapy until infection is resolved. - Use caution in pregnancy: discuss risks with a specialist before exposure. - Adjust dose in renal impairment: reduce dosage according to renal function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Azathioprine interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol or febuxostat: markedly increase azathioprine toxicity; concurrent use is contraindicated. - Ribavirin: synergistic bone‑marrow suppression may be life‑threatening. - High‑dose warfarin: potentiates anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance renal toxicity; monitor renal function. - ACE inhibitors or ARBs: combined effect on kidney function warrants periodic labs. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk. - Trimethoprim‑sulfamethoxazole: may augment bone‑marrow suppression; observe blood counts.